|
TOP STORY |
ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death No plasma biomarkers are associated with the response of acute graft-versus-host disease (GVHD) to therapy after allogeneic hematopoietic stem-cell transplantation. Researchers compared 12 biomarkers in plasma obtained a median of 16 days after therapy initiation from 10 patients with a complete response by day 28 after therapy initiation and in plasma obtained from 10 patients with progressive GVHD during therapy. [N Engl J Med] Abstract | Press Release |
PUBLICATIONS (Ranked by impact factor of the journal) |
Induction of Intestinal Stem Cells by R-Spondin 1 and Slit2 Augments Chemoradioprotection Scientists tested whether the induction of adult stem cells could repair chemoradiation-induced tissue injury and prolong overall survival in mice. They found that intestinal stem cells (ISCs) expressed Slit2 and its single-span transmembrane cell-surface receptor roundabout 1 (Robo1). Partial genetic deletion of Robo1 decreased ISC numbers and caused villus hypotrophy, whereas a Slit2 transgene increased ISC numbers and triggered villus hypertrophy. [Nature] Abstract | Press Release Second Allograft for Hematologic Relapse of Acute Leukemia after First Allogeneic Stem-Cell Transplantation from Related and Unrelated Donors: The Role of Donor Change Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells Inhibition of Pluripotent Stem Cell-Derived Teratoma Formation by Small Molecules STAT3-Mutations Indicate the Presence of Subclinical T Cell Clones in a Subset of Aplastic Anemia and Myelodysplastic Syndrome Patients Dynamic Compaction of Human Mesenchymal Stem/Precursor Cells (MSC) into Spheres Self-Activates Caspase-Dependent IL1 Signaling to Enhance Secretion of Modulators of Inflammation and Immunity (PGE2, TSG6 and STC1) Stem Cell Transplantation for Follicular Lymphoma Relapsed/Refractory after Prior Rituximab Transplantation of Human Fetal-Derived Neural Stem Cells Improves Cognitive Function Following Cranial Irradiation Intravenous Administration of Human Umbilical Cord Blood-Derived AC133+ Endothelial Progenitor Cells in Rat Stroke Model Reduces Infarct Volume: Magnetic Resonance Imaging and Histological Findings The Timing of Neural Stem Cell-Based Virotherapy Is Critical for Optimal Therapeutic Efficacy When Applied with Radiation and Chemotherapy for the Treatment of Glioblastoma |
REVIEWS |
Cancer Gene Discovery: Exploiting Insertional Mutagenesis The authors describe various insertional mutagens focusing on their advantages/limitations and discuss the new and promising tools that will improve the insertional mutagenesis screens of the future. [Mol Can Res] Abstract Visit our reviews page to see a complete list of reviews in the cell, gene and immunotherapy research field. |
SCIENCE NEWS |
Vical Phase III Trial of Allovectin® Fails to Meet Efficacy Endpoints Vical Incorporated announced top-line results from a Phase III trial of Allovectin® (velimogene aliplasmid), an investigational intratumoral cancer immunotherapy, in patients with metastatic melanoma. The 390-subject trial failed to demonstrate a statistically significant improvement vs. first-line chemotherapy for either the primary endpoint of objective response rate at 24 weeks or more after randomization or the secondary endpoint of overall survival. [Vical, Inc.] Press Release |
POLICY |
Famous HeLa Cells Get Genetic Close-Up, and New Data-Sharing Rules Five months after it was hastily removed from the Internet in the face of harsh criticism, the genome of the widely used HeLa cell line is back online. Not only that, but it is also now sequenced at the highest level of resolution yet for a cancer research cell line. But scientists who want to use those data must now ask for permission from a committee that includes descendants of the woman whose cells were taken-without her consent-62 years ago. [U.S. National Institutes of Health] Press Release House Panel Trains Sights on Unregulated Stem-Cell Therapy in the Philippines |
BUSINESS |
Sanguine BioSciences Announces Distribution Partnership with AMS Biotechnology Sanguine BioSciences announced a distribution partnership with AMS Biotechnology to make its products and services available to researchers in Europe. Sanguine collects and de-identifies biospecimen, medical history and other data from patients diagnosed with severe and chronic diseases for use in biomarker research. [PR Newswire Association LLC] Press Release Stem Cell Therapeutics Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets Athersys Announces Grant to Support Clinical Advancement of Its MultiStem® Regenerative Medicine Program for Heart Attack Patients Pilot Clinical Study into iPS Cell Therapy for Eye Disease Starts in Japan ASU-Mayo Research Project Targets Carpal Tunnel Syndrome Diagnosis Stratatech Awarded BARDA Contract Valued Up to $47.2 Million for Advanced Development of StrataGraft® Skin Tissue for Thermal Burns Cardium Reports on New Excellagen-Based Stromal Cell Research for Wound Healing with Orbsen Therapeutics under European FP7 REDDSTAR Diabetes Initiative Northwest Biotherapeutics Receives Regulatory Decision that Will Enable Its Phase III Brain Cancer Trial to Proceed in Germany Kite Pharma Appoints Leading Cancer Immunotherapy Experts to Its Scientific Advisory Board BioRestorative Therapies Receives Approval to Conduct Retrospective Safety Study on Its Bulging/Herniated Disc Procedure |
NIH |
Intestinal Stem Cell Consortium Research Projects (RFA-DK-13-012) Limited Competition for the Intestinal Stem Cell Consortium Coordinating Center (RFA-DK-13-505) |
CBER |
Circular of Information for the Use of Human Blood and Blood Components |
REGULATORY |
Food and Drug Administration (United States) Guidance for Industry: Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring |
EVENTS |
NEW Advances in Cellular Assays & Cell Culture May 14-15, 2014 Barcelona, Spain Visit our events page to see a complete list of events in the cell, gene and immunotherapy community. |
JOB OPPORTUNITIES |
NEW Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.) Tenure-Track Position – Cell Biologist (McGill University) Postdoctoral Positions – AIDS Vaccine and Human Gene Therapy (GeneCure Biotechnologies) Postdoctoral Fellowship – Immunology (Johns Hopkins University School of Medicine) Director of Cell Processing Facility (S L Collins Associates, Inc.) Postdoctoral Researcher – Hematopoietic Stem Cells (Albert Einstein College of Medicine) |
SUBSCRIBER TOOLS: | |||
Profile Center | Connexon Publications | Article Submission | Contact Us |